Alkermes plc (ALKS)

23.65 -0.11 (-0.46%) As of 02:57PM EDT. Market open.

Alkermes plc

Connaught House
1 Burlington Road Dublin 4
Dublin D04 C5Y6
Ireland
353 1 772 8000
https://www.alkermes.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 2,100

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard F. Pops	Chairman & CEO	2.3M	5.15M	1962
Mr. David Joseph Gaffin	Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary	1.08M	N/A	1972
Mr. Iain Michael Brown	Senior VP & CFO (Leave of Absence)	867.75k	N/A	1969
Dr. Craig C. Hopkinson M.D.	Executive VP of Research & Development and Chief Medical Officer	1.12M	N/A	1968
Dr. Floyd E. Bloom M.D.	Founder	57.73k	N/A	1937
Mr. Samuel J. Parisi	Interim Principal Accounting Officer & VP of Finance	N/A	N/A	1975
Mr. Thomas Harvey	Chief Information Officer & Senior VP of IT	N/A	N/A	N/A
Ms. Sandra Coombs	Senior Vice President of Corporate Affairs & Investor Relations	N/A	N/A	N/A
Mr. Stephen Schiavo	Senior Vice President of Human Resources	N/A	N/A	N/A
Mr. Peter Norman	Senior Vice President of Policy & Government Relations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Corporate governance

Alkermes plc’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.